Johnson & Johnson Beheer

Beheer criteriumcontroles 2/4

De CEO Johnson & Johnson is Joaquin Duato, benoemd in Jan2022, heeft een ambtstermijn van 2.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 28.40M, bestaande uit 5.6% salaris en 94.4% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.015% van de aandelen van het bedrijf, ter waarde CHF 50.16M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5 jaar en 4.9 jaar.

Belangrijke informatie

Joaquin Duato

Algemeen directeur

US$28.4m

Totale compensatie

Percentage CEO-salaris	5.6%
Dienstverband CEO	2.8yrs
Eigendom CEO	0.02%
Management gemiddelde ambtstermijn	5yrs
Gemiddelde ambtstermijn bestuur	4.9yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Joaquin Duato's beloning veranderd ten opzichte van Johnson & Johnson's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 29 2024	n/a	n/a	US$15b
Jun 30 2024	n/a	n/a	US$16b
Mar 31 2024	n/a	n/a	US$17b
Dec 31 2023	US$28m	US$2m	US$13b
Oct 01 2023	n/a	n/a	US$12b
Jul 02 2023	n/a	n/a	US$12b
Apr 02 2023	n/a	n/a	US$11b
Jan 01 2023	US$13m	US$1m	US$16b
Oct 02 2022	n/a	n/a	US$18b
Jul 03 2022	n/a	n/a	US$17b
Apr 03 2022	n/a	n/a	US$20b
Jan 02 2022	US$14m	US$1m	US$18b
Oct 03 2021	n/a	n/a	US$18b
Jul 04 2021	n/a	n/a	US$18b
Apr 04 2021	n/a	n/a	US$15b
Jan 03 2021	n/a	n/a	US$15b
Sep 27 2020	n/a	n/a	US$17b
Jun 28 2020	n/a	n/a	US$15b
Mar 29 2020	n/a	n/a	US$17b
Dec 29 2019	US$13m	US$970k	US$15b
Sep 29 2019	n/a	n/a	US$14b
Jun 30 2019	n/a	n/a	US$16b
Mar 31 2019	n/a	n/a	US$15b
Dec 30 2018	US$9m	US$934k	US$15b
Sep 30 2018	n/a	n/a	US$2b
Jul 01 2018	n/a	n/a	US$1b
Apr 01 2018	n/a	n/a	US$1b
Dec 31 2017	US$19m	US$897k	US$1b

Compensatie versus markt: De totale vergoeding ($USD 28.40M ) Joaquin } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Swiss markt ($USD 4.73M ).

Compensatie versus inkomsten: De vergoeding van Joaquin is het afgelopen jaar met meer dan 20% gestegen.

CEO

Joaquin Duato (61 yo)

2.8yrs

Tenure

US$28,397,240

Compensatie

Mr. Joaquin Duato serves as Chief Executive Officer & Director of Johnson & Johnson since January 3, 2022 and serves as its Chairman since January 02, 2023. He served as Worldwide Chairman of Pharmaceutica...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Joaquin Duato	CEO & Chairman	2.8yrs	US$28.40m	0.015% CHF 50.2m
Joseph Wolk	Executive VP & CFO	6.3yrs	US$13.91m	0.0029% CHF 9.8m
Peter Fasolo	Executive VP & Chief Human Resources Officer	8.6yrs	US$7.50m	0.0047% CHF 15.4m
Jennifer Taubert	Executive VP & Worldwide Chairman of Innovative Medicine	12.8yrs	US$11.00m	0.0064% CHF 21.3m
John Reed	Executive Vice President of Innovative Medicine	1.6yrs	US$20.65m	0.00061% CHF 2.0m
Robert Decker	Controller & Chief Accounting Officer	4.9yrs	geen gegevens	0.00082% CHF 2.7m
James Swanson	Executive VP & Chief Information Officer	5yrs	geen gegevens	0.00061% CHF 2.0m
Jessica Moore	Vice President of Investor Relations	3yrs	geen gegevens	geen gegevens
Dirk Brinckman	Chief Compliance Officer	no data	geen gegevens	geen gegevens
Elizabeth Forminard	Executive VP & Chief Legal Officer	2.1yrs	geen gegevens	0.00035% CHF 1.2m
Guy Lebeau	Group Chairman of MD&D Business - EMEA	no data	geen gegevens	geen gegevens
Kathryn Wengel	Executive VP and Chief Technical Operations & Risk Officer	6.3yrs	geen gegevens	0.0034% CHF 11.4m

5.0yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 000943981 wordt beschouwd als ervaren (gemiddelde ambtstermijn 5 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Joaquin Duato	CEO & Chairman	2.8yrs	US$28.40m	0.015% CHF 50.2m
Anne Mulcahy	Independent Director	15.8yrs	US$410.00k	0.00034% CHF 1.1m
Hubert Joly	Independent Director	4.9yrs	US$320.00k	0.00021% CHF 696.2k
Marillyn Hewson	Lead Independent Director	5.6yrs	US$360.00k	0.00012% CHF 397.8k
Paula Johnson	Independent Director	1.8yrs	US$352.97k	0.000010% CHF 33.2k
Mark McClellan	Independent Director	11.1yrs	US$320.00k	0% CHF 0
Mary Beckerle	Independent Director	9.4yrs	US$355.00k	0% CHF 0
Darius Adamczyk	Independent Director	2.8yrs	US$340.00k	0.000040% CHF 132.6k
Jennifer Doudna	Independent Director	6.6yrs	US$320.00k	0% CHF 0
Eugene Woods	Independent Director	less than a year	US$89.15k	geen gegevens
Mark Weinberger	Independent Director	4.9yrs	US$340.00k	0% CHF 0
Nadja West	Independent Director	3.9yrs	US$340.00k	0% CHF 0

4.9yrs

Gemiddelde duur

62.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 000943981 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.9 jaar).

Johnson & Johnson Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Johnson & Johnson Announces the Retirement of D. S. Davis as Director and Committee Changes

Johnson & Johnson Announces Executive Changes

Recent updates

Johnson & Johnson Seeks U.S. FDA Approval for Subcutaneous Induction Regimen of Tremfya (Guselkumab) inulcerative Colitis, A First for an IL-23 Inhibitor

Upcoming dividend of US$1.24 per share

Johnson & Johnson Announces Results from Additional Analyses of the Phase 2 DAHLIA Study Highlighting Improvement in Key Measures of Disease Activity and IgG Reduction

Johnson & Johnson Announces U.S. Food and Drug Administration Grants Nipocalimab Breakthrough Therapy Designation for the Treatment of Adults Living with Moderate-To-Severe Sjogren's Disease

Johnson & Johnson Submits Applications in the U.S. and EU Seek Approval of DARZALEX FASPRO® as Subcutaneous Monotherapy for High-Risk Smoldering Multiple Myeloma

Johnson & Johnson Announces Results from Phase 3 GRAVITI Study of Tremfya

Johnson & Johnson Highlights Innovative Neuropsychiatry Portfolio and Pipeline at Psych Congress

Johnson & Johnson Announces New Spectrem Study Findings Reveal Tremfya (Guselkumab) Effectively Clears Overlooked and Undertreated Plaque Psoriasis

Third quarter dividend of US$1.24 announced

Connecticut Jury Delivers $15 Million Asbestos Verdict Against Johnson & Johnson

Third quarter 2024 earnings released: EPS: US$1.11 (vs US$1.71 in 3Q 2023)

Johnson & Johnson Announces Positive Results from the Phase 2/3 Vibrance-MG Study of Nipocalimab

Johnson & Johnson Announces Tremfya Data in Both Crohn's Disease and Ulcerative Colitis

Johnson & Johnson Announces the Results of A Landmark Real-World, Head-To-Head Study Showing That Erleada (Apalutamide)

Johnson & Johnson Files for U.S. FDA Approval of DARZALEX FASPRO-Based Quadruplet Regimen for Newly Diagnosed Multiple Myeloma Patients for Whom Transplant Is Not Planned

Johnson & Johnson Announces Data from Three Studies Highlighting Clinical Efficacy of Darzalex® (Daratumumab) and Darzalex Faspro in Maintenance Regimens

Johnson & Johnson Announces Interim Data from the Ongoing Phase 2 Sunrise-4 Study Showing Neoadjuvant Treatment with Investigational Tar-200 Plus Cetrelimab

Johnson & Johnson Announces Updated Results from the Phase 3 Mariposa-2 Study Which Showed Rybrevant (Amivantamab-Vmjw)

Johnson & Johnson Announces the Retirement of D. S. Davis as Director and Committee Changes

Johnson & Johnson to Report Q4, 2024 Results on Jan 22, 2025

Johnson & Johnson Seeks First Approval of Nipocalimab to Treat Broadest Population Living with Antibody Positive Generalized Myasthenia Gravis

Johnson & Johnson Announces Executive Changes

Upcoming dividend of US$1.24 per share

Johnson & Johnson Announces U.S. Food and Drug Administration Approves Rybrevant® (Amivantamab-Vmjw) Plus Lazcluze™ (Lazertinib)

Johnson & Johnson Announces Results from the Phase 2 Open-Label UNITY Study of Nipocalimab for the Treatment of Alloimmunized Pregnant Individuals

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd